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Abstract
Aneurysms-osteoarthritis syndrome (AOS) is characterized by arterial aneurysms and dis-
section in combination with early-onset osteoarthritis, which can impact quality of life.
We describe the subjective quality of life and investigate anxiety and depression in
28 AOS patients aged 15–73 years. Three questionnaires were used: 36-Item Short
Form Survey (SF-36), hospital anxiety and depression scale (HADS) and Rotterdam dis-
ease specific questionnaire. Results of the SF-36 and HADS were compared to a refer-
ence Dutch cohort and the SF-36 questionnaire also to patients with Marfan syndrome.
Compared to the general population, AOS patients scored significantly lower on the fol-
lowing SF-36 domains: physical functioning, vitality, social functioning, bodily pain, and
general health. Physical functioning was also lower than in Marfan patients. Patients with
AOS scored higher on the HADS depression scale, while anxiety did not show a signifi-
cant difference compared to the general population. No difference in SF-36 and HADS
domain scores were found between patient with andwithout orthopaedic symptoms and
patients with or without previous aortic surgery. Additionally, we found that patients'
worries for their future and heredity of their disease are important factors for anxiety,
which should be addressed in clinical practice.
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1 | INTRODUCTION
An aneurysm or dilatation of the thoracic aorta can cause aortic dissec-
tion, which is a potentially life threatening event as over half of all
patients with an acute thoracic aortic dissection die within 30 days
(Melvinsdottir et al., 2016). In 20% of the patients an aortic aneurysm
results from a heritable thoracic aortic disease (HTAD) (Caglayan &
Dundar, 2009; Hannuksela, Stattin, Johansson, & Carlberg, 2015). In
2011, a new HTAD was described, the so-called “aneurysms-
osteoarthritis syndrome (AOS),” caused by a pathogenic variant in the
SMAD3 gene (van de Laar et al., 2011), which is part of the TGF-β path-
way. Aneurysms-osteoarthritis syndrome has many similarities with
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Loeys–Dietz syndrome (LDS), and is therefore also referred to as LDS
type 3. In AOS, aneurysms can occur within the aorta and other arteries
(among which the splenic, iliac, hepatic, and intracranial arteries). Fur-
thermore, the arteries show tortuosity and aortic dissections or ruptures
already occur in a mildly dilated aorta. In 18% of the patients aortic dis-
section is even the first manifestation of the disease (van der Linde et al.,
2012). In addition to the vascular findings, joint abnormalities are an
important feature of this syndrome, which are often the reason for first
presentation. These joint abnormalities include osteoarthritis and
osteochondritis dissecans at a relatively young age (van de Laar et al.,
2012). Other characteristics associated with pathogenic variants in the
SMAD3 gene are widely spaced eyes, bifid uvula, umbilical or inguinal
hernias varices, velvety skin, and striae (van de Laar et al., 2011). These
physical symptoms and the risk of life threatening dissection of the arter-
ies might cause reduced quality of life, anxiety, and depression. Anxiety
in AOS patients can also be caused by experiencing the consequences of
the disease through relatives, since this autosomal dominant genetic dis-
order is often diagnosed in multiple family members. Therefore knowl-
edge about psychological well-being and causes of impaired quality of
life and anxiety or depression in AOS patients is important in order to
develop specific management strategies. Although psychosocial well-
being has been investigated for other vasculopathies such as Marfan
syndrome (Gritti et al., 2015) and Ehlers–Danlos (Berglund, Pettersson,
Pigg, & Kristiansson, 2015), no attention has been paid yet to the quality
of life and occurrence of depression or anxiety in patients with this life-
threatening syndrome. Therefore, the aim of this study was to compre-
hensively describe the subjective quality of life and investigate anxiety
and depression in AOS patients.
2 | MATERIALS AND METHODS
2.1 | Study population
All carriers of a pathogenic variant in the SMAD3 gene undergoing
follow-up in our tertiary center per in-house protocol since January
2009 were invited for this study. Family members which were 50% risk
carrierswith obviousAOS related symptoms (aortic dilatation or osteoar-
thritis at an early age) were also included. Demographic and clinical data
were obtained from the electronic patient files. Diabetes mellitus was
defined as current use of medication. As part of our protocol, all patients
underwent echocardiography and whole-body computed tomography
angiography (CTA). The aortic measurements of the sinus of Valsalva,
ascending aorta, aortic arch, and descending aorta were measured using
the inner edge-to-inner edge method on the most recent CTA. Aneu-
rysms and dissections were categorized by the following locations and
definition: head and neck, thoracic, coronary, abdominal, leg and/or arm
or pulmonary artery. Information on the following valvular, ventricular
and arrhythmic abnormalities was collected: bicuspid aortic valve, aortic
stenosis (Vmax >2.5 m/s), aortic regurgitation (at least moderate)
(Lancellotti et al., 2013), valvular disease other than from the aortic valve,
congenital heart disorders, ventricular hypertrophy (septal wall>13 mm),
left ventricular dilatation (diastolic diameter >60 mm), and atrial fibrilla-
tion (former, paroxysmal or current). The study complied with the
Declaration ofHelsinki andwas approved by themedical ethical commit-
tee of the ErasmusMedical Centre (MEC17-057).Written informed con-
sent was provided by all patients.
2.2 | Questionnaires
All participants received three questionnaires: the Short Form-36 Health
Survey (SF-36) (Ware & Sherbourne, 1992), the hospital anxiety and
depression scale (HADS) (Snaith, 2003) and the Rotterdam disease spe-
cific questionnaire. The questionnaires were sent at first on the 14th of
November 2017 andwere collected until the 1st of February 2018. If par-
ticipants did not respond at first, they received a maximum of two
reminders. The SF-36 was used to determine patient-reported quality of
life. It covers the following eight domains: physical functioning, role limita-
tions due to physical health, bodily pain, general health, mental health,
role limitations due to mental health, vitality (energy or fatigue related),
and social functioning. The scale ranges from 0 through 100 points.
A lower score per subcategory reflects a lower quality of life on that life
domain. In addition, two sum scores, the mental component summary
(MCS) and physical component summary (PCS), were calculated (Ware
JE, 1994). These summary scores are standardized according to the gen-
eral Dutch population (Aaronson et al., 1998), whichmeans that all scores
above and below 50 are above and below the average in theDutch popu-
lation. The HADS questionnaire determines the levels of anxiety and
depression on two subscales with a total score ranking from 1 to 21.
A score of 0–7 for either subscale is in the normal range, a score of 8–10
is possible abnormal and 11 or higher indicates the probable presence of
anxiety or depression. The “Rotterdam disease specific questionnaire”
was developed by ourmultidisciplinary team in the ErasmusMedical Cen-
ter (Supporting information) to investigate the impact of having AOS
related aortic aneurysm on daily life, work participation, sexual function-
ing, pregnancy wish, and sports participation. Patients received 18 state-
ments and were asked to grade how they felt on a continuous scale from
0 to 10, 0 being “I completely disagree” and10 being “I completely agree”.
2.3 | Comparison with the general population and
other aortic disease patients (Marfan syndrome)
For the HADS and SF-36 questionnaires we compared our data to the
reference values of the age-matched general Dutch population
(Aaronson et al., 1998; Spinhoven et al., 1997). For the SF-36, a cohort of
age and sex matched Marfan patients was also available, which allowed
us to compare AOS with another syndromic HTAD (Rand-Hendriksen
et al., 2010). For the results of the Rotterdam disease specific question-
naire, there are no reference values available yet, because this question-
naire was newly developed for this study's aim.
2.4 | Statistical analysis
Continuous variables with a normal distribution were reported as mean
with ± SD and the median and interquartile range was reported in case
of non-normal distribution. Categorical variables were summarized as
frequencies and percentages. Data distribution was checked using
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histograms. Because of the non-normally distribution of the values in the
domains of the SF-36 and HADS questionnaires, the median and inter-
quartile ranges are presented in table 1 and the p-value of the one-
sample Wilcoxon signed rank test was presented in the text and figures.
With the one-sampleWilcoxon signed rank test the median of a continu-
ous variable in our cohort was compared with a hypothesized median of
a reference group. Since our reference article showed their values only
with mean ± SD, we assumed that the variables were distributed nor-
mally. Because mean and median are comparable in normally distributed
variables, we used the mean of the reference as hypothesized median in
our nonparametric test. To visually compare our datawith reference data
presented as mean ± SD, also our data were presented as mean ± SD in
the figures although we could not proof normal distribution. However,
only small differences were found between the calculated mean and
median of the HADS and SF-36 domain scores. To further investigate if
patients with orthopaedic symptoms or previous aortic surgery had
higher levels on the SF-36 and HADS domains, we performed the
Mann–WhitneyU test. A p-value of less than 0.05was considered statis-
tically significant. All statistical analyses were performed using the Statis-
tical Package for Social Sciences (Released 2012. IBM SPSS Statistics for
Windows, Version 21.0. Armonk, NewYork: IBMCorp).
3 | RESULTS
3.1 | Study population
Of the 31 patients with AOS in our center, 28 patients (90%) agreed to
participate and returned the questionnaires. The other three patients
were approached two times, but could not be reached (n = 2) or decided
not to participate due to time-constraints (n = 1). There were no major
differences between the 28 responders and 3 nonresponders. The base-
line characteristics of the 28 study patients are presented in Table 2. Our
cohort contained 23 participants with a confirmed SMAD3 mutation
representing 10 different genetic mutations with the most common
heterozygous mutation (R287W, 859C>T, SMAD3 ex 9) present in
9 patients. The mean age was 44.0 ± 17.3 years with an age range from
15 to 73 years. Of the 28 patients, 17 (61%) were women. Cardiac or
vascular abnormalities were present in 22 (79%) patients and orthopae-
dic symptoms were present in 24 (86%) patients. In 18 (64%) of the
28 patients both cardiovascular manifestations and orthopaedic symp-
tomswere reported.
3.2 | Quality of life, anxiety, and depression
The median values with interquartile range of the domains from the
SF-36 and HADS questionnaires are presented in Table 1. Our cohort
scored significantly lower compared to the age-matched reference group
of 1,742Dutch citizens (Aaronson et al., 1998) on the following domains:
physical functioning (p < .001), role limitations physical health (p = .001),
bodily pain (p = .001), general health (p < .001), vitality (p < .001), and
social functioning (p = .002). AOS patients showed a standardized PCS
score of 34.3 (25.0–48.2) and a MCS score of 50.4 (39.4–59.9). When
comparing the SF-36 with age-matched Marfan patients, only physical
health was lower in patients with AOS (p = .005). The mean values with
standard deviation of the domains from the SF-36 questionnaire for
AOS patients, Marfan patients and the reference group are visualized in
Figure 1.
The HADS questionnaire showed no differences in anxiety
(median 5.0 vs. 5.1, p = .569) between AOS patients and the general
population. However, patients with AOS scored higher on the depres-
sion subscale (median 5.0 vs. 3.4, p = .036) compared to a sample of
199 Dutch adults (Spinhoven et al., 1997). In our population of AOS
patients, two patients (7%) scored above the cut-off, indicative for
clinical depression, while one patient (4%) scored in the range for clini-
cal anxiety. The mean values with standard deviation of the domains
from the HADS questionnaire are shown in Figure 2 for the AOS
patients and the reference group.
TABLE 1 Results of SF-36 and HADS in patients with AOS
Domain/scales Score Summary measuresa Score
SF-36 Physical functioning 45.0 (30.0–78.8) PCS 34.3 (25.0–48.2)
Role limitations due to physical health 37.5 (0.0–100.0)
Bodily pain 57.5 (35.0–75.0)
General health 40.0 (25.0–55.0)
Mental health 76.0 (57.0–88.0) MCS 50.4 (39.4–59.9)
Role limitations due to mental health 100.0 (33.3–100.0)
Vitality 50.0 (20.0–63.8)
Social functioning 62.5 (50.0–87.5)
HADS Depression scale 5.0 (2.0–9.8)
Anxiety scale 5.0 (2.0–7.8)
Note: Data is shown as median (25–75%).
Abbreviations: AOS, aneurysms-osteoarthritis syndrome; HADS, hospital anxiety and depression scale; MCS, mental component summary; PCS, physical
component summary.
aStandardized scores with use of the general Dutch population (Aaronson et al., 1998).
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No significant differences in SF-36 and HADS domain scores were
found between patient with and without orthopaedic symptoms and
patients with or without previous aortic surgery.
3.3 | Disease specific anxieties/concerns
In the Rotterdam disease specific questionnaire, the majority of the
patients reported fear and/or anxiety according to their future or the
future of their siblings or offspring's (Figure 3). Concerns about dying at
an early age (median 3.5, IQR 1.0–7.0), future health (median 5.0, IQR
2.3–7.0), future surgery (median 6.5, IQR 1.0–9.0) and heredity of their
disease (median 7.0, IQR 4.3–10.0) werementioned. The risk of develop-
ing aortic dilatation or dissection or already having aortic pathology did
not have a significant impact on participation in work, hobbies, sexual
activities, and physical activities.
4 | DISCUSSION
The results of our study show that patients with AOS report a lower
quality of life, mainly on the physical health subscales, and higher
scores on the depression subscale compared to the general Dutch
population. Disease specific anxiety was most often related to the
future of their own health or the health of their close relatives.
Although anxiety, depression, and quality of life have been described
in other patients groups with aortic pathology (Boman, Bryman, & Moller,
2004; Goldfinger et al., 2017; Winnerkvist, Brorsson, & Radegran, 2006),
specifically after thoracic aortic surgery (Okamoto, Motomura,
Murashima, & Takamoto, 2013), it has not yet been described in
AOS patients or Loeys–Dietz syndrome. In general, AOS is not a
very well-known syndrome among cardiologist and other special-
ists, while pathogenic variants in the SMAD3 gene are responsible
for 2% of familial thoracic aortic disease (Regalado et al., 2011).
TABLE 2 Baseline characteristics
Baseline characteristics
AOS
patients (N = 28)
Sex (female) 17 (61%)
Age (years) 44.0 ± 17.3
Confirmed SMAD3 mutation carriersa 23 (82%)
BMI (kg/m2) 24.9 ± 3.4
Smoking (currently) 2 (7%)
Systolic blood pressure (mmHg) 128.2 ± 16.9
Diastolic blood pressure (mmHg) 80.4 ± 9.5
Medication use 14 (50%)
Beta-blocker 8 (29%)
Diuretics 0 (0%)
ACE inhibitors 4 (14%)
Angiotensin receptor blocker 2 (7%)
Calcium channel blocker 0 (0%)
Cholesterol lowering drugs (statins or other) 3 (11%)
Platelet inhibitor 6 (21%)
Oral anticoagulant 2 (7%)
Comorbidity 4 (14%)
Diabetes mellitus 0 (0%)
Coronary artery disease 1 (4%)
Aortic aneurysm or dissection 19 (68%)
History of aortic surgery 9 (32%)
Thoracic aortic aneurysms (>40 mm)b 5 (18%)
Head and neck arterial anomaly 6 (21%)
Coronary arterial anomaly 0 (0%)
Abdominal arterial anomaly 5 (18%)
Leg or arm arterial anomaly 0 (0%)
Pulmonary artery dilatation (>40 mm) 2 (7%)
Aortic diameterb
Sinus of Valsalva 36.0 ± 3.5
(range 30–44)
Ascending aorta 30.6 ± 3.6
(range 25–40)
Aortic arch 26.5 ± 3.7
(range 21–34)
Descending aorta 24.9 ± 3.4
(range 19–33)
Cardiac anomalies 9 (32%)
Bicuspid valve 0 (0%)
Aortic stenosis (Vmax >250 m/s) 0 (0%)
Aortic regurgitation (at least moderate) 0 (0%)
Valve disease other than aortic (at least
moderate)
1 (4%)c
Congenital heart disease (i.e., VSD) 1 (4%)
Ventricular hypertrophy (>13 mm) 2 (7%)
Left ventricular dilatation (>60 mm) 2 (7%)
(Continues)
TABLE 2 (Continued)
Baseline characteristics
AOS
patients (N = 28)
Atrial fibrillation (former/paroxysmal or
currently)
4 (14%)
Age first vascular or cardiac abnormalities (in
years)
38.0 (26.5–56.0)
Orthopaedic abnormalitiesd 24 (86%)
Age first orthopaedic abnormalities (in years) 20.0 (13.8–46.0)
Note: Data is shown as median (25–75%), mean ± SD or as N (%). Missing
values for BMI (n = 2).
aFive patients have a 50% chance of having AOS, since they are not yet
genetically tested. They are included because they showed significant
aortic, cardiac or orthopaedic symptoms associated with AOS.
bAortic diameters of the sinus of Valsalva and ascending aorta and
prevalence of thoracic aortic aneurysm (>40 mm) are presented for
patients who have not undergone aortic surgery.
cThis patients showed moderate mitral valve regurgitation.
dOrthopaedic abnormalities such as arthritis, arthrosis, osteochondritis
dissecans, orthopaedic surgeries, osteosarcomas, instability of the joints,
joint or muscle pain.
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This patient group is of great interest, because of their recently dis-
covered extensive presentation including severe joint abnormalities
and most importantly aggressive cardiovascular phenotype requiring vigi-
lant follow-up (van der Linde et al., 2012). Therefore it is important for all
clinicians involved in the care for these patients to be aware of the psy-
chological aspects in order to provide adequate care. We showed lower
SF-36 scores, on almost all domains compared to the general population
(Aaronson et al., 1998). The median PCS score of our patients with path-
ogenic variants in the SMAD3 gene was 34.3, which means a much lower
physical health than the general population, while the median MCS score
(50.4) showed that mental health was comparable with the general popu-
lation. However, on two subscales of mental health, namely vitality and
social functioning, AOS patient did score lower than the general popula-
tion. We know that middle aged Dutch patients with congenital heart
disease show similar or even more favorable levels compared to
normative data using the SF-36 survey (Opic et al., 2016). This difference
between patients with congenital heart disease and AOS patients can be
explained by the moment at which the symptoms are present. Orthopae-
dic and cardiovascular symptoms associated with AOS start at a median
age of 22 and 38 years respectively, which cause an acute change in
patients' health with clear impact on quality of life. Whereas the patient
with congenital heart disease are known with their defect from birth,
AOS patients need to adapt and accept that they have this disease at
later age. Compared to patients with Marfan syndrome (Rand-
Hendriksen et al., 2010), AOS patients scored only lower on the SF-36
questionnaire for the domain of physical functioning. This can be a result
of the more extensive presentation of musculoskeletal complaints in
patients with AOS including osteoarthritis, osteochondritis dissecans,
scoliosis, and pectus excavatum (Loeys et al., 2010; van de Laar et al.,
2012). This assumption is supported by data from patients with Ehlers–
F IGURE 1 Comparison of eight SF-36 domains between AOS patients, Marfan patients and healthy control. Data is shown as mean
(incl. 95% CI). The SF-36 scale ranges from 0 through 100 points. The lower the point count per subcategory, the more prevalent it is that the
individual has a negative effect of that sub scale's premise. For social functioning and general health one patient was missing, because he forgets
to fill in one page of the questionnaire. * Significant lower compared to the mean of the general population (One-sample Wilcoxon signed rank
test). † Significant lower compared to both the mean of the general population and the mean of patients with Marfan syndrome (One-sample
Wilcoxon signed rank test). AOS, aneurysms-osteoarthritis syndrome; BP, bodily pain; GH, general health; HADS, hospital anxiety and depression
scale; MH, mental health; PF, physical functioning; RM, role limitations due to mental health; RP, role limitations due to physical health; SF, social
functioning; VT, vitality
F IGURE 2 Comparison of two HADS domains between AOS patients and healthy control. Data is shown as mean (incl. 95% CI). The anxiety
and depression sub scales have a point system of 0 through 21 points total. The higher the point count for any sub scale, the more likely that the
individual suffers from anxiety or depression. *Significant higher compared to the general population (one-sample Wilcoxon signed rank test)
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Danlos syndrome, a connective tissue disorder which presents with
extreme musculoskeletal symptoms including hypermobility (De Paepe &
Malfait, 2012). Ehlers–Danlos patients report even lower physical function
score (39.6) and general health score (26.8) compared to AOS patients
(Berglund et al., 2015; Bovet, Carlson, & Taylor, 2016). We did not find a
difference between patients with and without orthopaedic symptoms.
However, this should be tested in larger cohorts, since our cohort might
be too small to prove the association between orthopaedic symptoms and
reduced quality of life. In conclusion, AOS patients and probably also
patients with other heritable thoracic aortic disease, have lower quality of
life than the general population, but there seem to be some differences
between syndromes. By assessing quality of life, anxiety, and depression,
we found unfavorable outcomes and impairments, warranting attention
and in some cases treatment. In our population of patients with patho-
genic variants in the SMAD3 gene, 4% scored above the cut-off for clinical
anxiety, while 7% scored in the range for clinical depression. These per-
centages are comparable to or even slightly lower than the prevalence's in
the general German population, which are 5.2% for anxiety and 9.6% for
depression based on the HADS questionnaire (Hinz & Brahler, 2011).
However, the median of the continuous outcome of the depression scale
was higher inOAS patients than in the general population.With the devel-
opment of our own Rotterdam disease specific questionnaire, we were
able to identify patients concerns due to their disease. Most importantly,
patients report worries concerning the future of their own health or the
health of their close relatives. These results emphasize the need for physi-
cians to discuss patient's future and risk for family members and check in
each patient whether someone is concerned about this. This is not only
important for AOS, but for all inherited syndromes. Generic questionnaires
such as SF-36 or EuroQol (EQ-5D) are commonly used for quality of life
assessment. Although the use of validated questionnaires is extremely
important, these questionnaires do not distinguish between quality of life
based on the disease itself or as a result of other problems like small or
short-term injuries and life events. With the use of more disease-specific
questionnaires, such as the Rotterdam disease specific questionnaire, in
larger cohorts we will be able to identify the cause of physiological burden
in a disease more precisely in the future. Nevertheless, before using these
questionnaires in clinical practice, they should be validated.
4.1 | Limitations
In this study, we used questionnaires to measure self-reported quality of
life, anxiety, and depression, which may have caused documentation of
more complaints than patients would have mentioned spontaneously.
Also, it may cause some information bias, although we assume that the
high response rate of 90% reduced the chance of bias. Because of our sin-
gle center design, we included a small cohort, which prevented us from
extensive identification of factors associated with quality of life, anxiety,
or depression.
4.2 | Conclusion
In conclusion, our population of AOS patients showed reduced quality of
life in comparison with the general population on physical functioning,
role limitations due to physical functioning, bodily pain, general health,
F IGURE 3 Results of the Rotterdam disease specific questionnaire. This figure shows the influence of (possible) aortic dilatation or
dissection on different aspects of life. Data shown as median with interquartile range 25–75%
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vitality, and social functioning. Physical functioning was also lower than
inMarfan patients. Although the prevalence of depression was similar to
the general population, patients with AOS scored significantly higher on
the depression scale, which physicians must be aware of to provide good
medical care. Additionally, we found that patients' worries for their
future and heredity of their disease are important factors for anxiety,
which should be addressed in clinical practice.
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